Drug name - Viekira Pak (copackaged)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8501238 ABBVIE INC Anti-infective agents and uses thereof
Sep, 2028

(5 years from now)

US8188104 ABBVIE INC Anti-infective agents and uses thereof
May, 2029

(6 years from now)

US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(6 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(8 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(9 years from now)

CN103819537A ABBVIE INC Anti-Viral Compounds
May, 2017

(5 years ago)

CN104628655A ABBVIE INC Anti-Infection Pyridine And Application Thereof
Jul, 2017

(5 years ago)

CN104193729A ABBVIE INC Antiviral Compound
Sep, 2017

(5 years ago)

CN104628654A ABBVIE INC Anti-Infection Pyridine And Application Thereof
Oct, 2017

(4 years ago)

CN106986861A ABBVIE INC Antiviral Compound
Jun, 2020

(2 years ago)

CN103819459B ABBVIE INC Antiviral Compound
May, 2021

(1 year, 4 months ago)

CN103819459A ABBVIE INC Antiviral Compound
May, 2021

(1 year, 4 months ago)

CN102641271B ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Aug, 2021

(1 year, 1 month ago)

CN102641271A ABBVIE INC Hepatitis C Serine Protease Inhibitor Of Macrocyclic Compound
Aug, 2021

(1 year, 1 month ago)

CN102746240A ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Aug, 2021

(1 year, 1 month ago)

CN102746240B ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Aug, 2021

(1 year, 1 month ago)

CN101842360B ABBVIE INC Anti-Infection Pyridine And Application Thereof
Sep, 2028

(5 years from now)

CN101842360A ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Sep, 2028

(5 years from now)

CN101775017B ABBVIE INC Macrocyclic Compounds Of Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

CN101775017A ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

CN103172620A ABBVIE INC Antiviral Composition
Jun, 2030

(7 years from now)

CN103172620B ABBVIE INC Antiviral Compound
Jun, 2030

(7 years from now)

CN102333772A ABBVIE INC Anti-Viral Compounds
Jun, 2030

(7 years from now)

CN102333772B ABBVIE INC Antiviral Composition
Jun, 2030

(7 years from now)

CN103209686A ABBVIE INC Solid Composition
Jun, 2031

(8 years from now)

CN103209686B ABBVIE INC Solid Composition
Jun, 2031

(8 years from now)

CN103153988B ABBVIE INC Antiviral Compound
Oct, 2031

(9 years from now)

CN103153988A ABBVIE INC Anti-Viral Compounds
Oct, 2031

(9 years from now)

CN103354808A ABBVIE INC Antiviral Compound
Dec, 2031

(9 years from now)

CN103354808B ABBVIE INC Antiviral Compound
Dec, 2031

(9 years from now)

CN103596941A ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

CN103596941B ABBVIE INC Antiviral Compounds
Feb, 2032

(9 years from now)

CN108350016A ABBVIE INC Antiviral Tetrahydrofuran Derivatives
Sep, 2036

(13 years from now)

CN108350016B ABBVIE INC Antiviral Tetrahydrofuran Derivatives
Sep, 2036

(13 years from now)

IN287227B ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

IN200907222P1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2954892B1 ABBVIE INC Solid Compositions
Jun, 2020

(2 years ago)

EP2954892A1 ABBVIE INC Solid Compositions
Jun, 2020

(2 years ago)

EP2639226B1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Sep, 2028

(5 years from now)

EP2368882B1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Sep, 2028

(5 years from now)

EP2639226A1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Sep, 2028

(5 years from now)

EP2368882A1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Sep, 2028

(5 years from now)

EP2468285B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468285A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468286A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2805726B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468287B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2805726A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468286B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468287A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2340029A4 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Jan, 2030

(7 years from now)

EP2340029A2 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Jan, 2030

(7 years from now)

EP2203431B1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Jan, 2030

(7 years from now)

EP2203431A1 ABBVIE INC Anti-Infective Pyrimidines And Uses Thereof
Jan, 2030

(7 years from now)

EP2340029B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Jan, 2030

(7 years from now)

EP2455376A1 ABBVIE INC Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv)
Jun, 2030

(7 years from now)

EP2337781B1 ABBVIE INC Anti-Viral Compounds To Treat Hcv Infection
Jun, 2030

(7 years from now)

EP2628481B1 ABBVIE INC Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv
Jun, 2030

(7 years from now)

EP2628481A1 ABBVIE INC Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv
Jun, 2030

(7 years from now)

EP2337781A2 ABBVIE INC Anti-Viral Compounds To Treat Hcv Infection
Jun, 2030

(7 years from now)

EP2455376B1 ABBVIE INC Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv)
Jun, 2030

(7 years from now)

EP2368890B1 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2368890A1 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2368890B9 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2579854B1 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2579854B2 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2579854A1 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2692346A1 ABBVIE INC An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative
Oct, 2031

(9 years from now)

EP2692346B1 ABBVIE INC An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative
Oct, 2031

(9 years from now)

EP2678334B1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

EP2678334A1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268349 ABBVIE INC Solid pharmaceutical dosage form Aug, 2024

(1 year, 10 months from now)

US8399015 ABBVIE INC Solid pharmaceutical dosage form Aug, 2024

(1 year, 10 months from now)

US9139536 ABBVIE INC Anti-infective agents and uses thereof Nov, 2028

(6 years from now)

US9006387 ABBVIE INC Anti-viral compounds Jun, 2030

(7 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV Apr, 2031

(8 years from now)

US8686026 ABBVIE INC Solid compositions Jun, 2031

(8 years from now)

US8492386 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US8685984 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US8680106 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US8466159 ABBVIE INC Methods for treating HCV Sep, 2032

(9 years from now)

US10201542 ABBVIE INC Formulations of pyrimidinedione derivative compounds Oct, 2033

(11 years from now)

US9629841 ABBVIE INC Formulations of pyrimidinedione derivative compounds Oct, 2033

(11 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient

Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir, without ribavirin; Treatment of hcv infection using paritaprevir, ombitasvir, ritonavir, and dasabuvir with ribavirin.

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 250MG BASE;12.5MG, 75MG, 50MG TABLET;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.